PET-CT Amyvid Studies to Help Rule Out Alzheimer’s Disease
Wake Radiology physicians are among the first in the area to interpret cutting edge Amyvid (florbetapir) PET-CT studies that can help rule out Alzheimer’s Disease. Amyvid is the first FDA-approved agent for PET-CT brain imaging of amyloid plaques in patients with cognitive impairment who are being evaluated for Alzheimer’s and other causes. Amyvid and insurance Amyvid is not currently covered by Medicare or any major insurance plans. Lilly’s Reimbursement Support Program includes a call center (1-877-9-AMYVID or 1-877-926-9843 Monday-Friday, 8am-8pm ET) and web-based resources to assist with Amyvid reimbursement for patients, including:
General coverage inquiries
Billing and coding information
Assistance with prior authorization and precertification
Badges of Honor
Wake Radiology is proud to have received the highest accreditations possible from the American College of Radiology (ACR).